Mylan and TB Alliance Collaborate to Commercialize Pretomanid in Two Combination Regimens for Tuberculosis
Shots:
- Mylan to get manufacturing & commercialization rights of pretomanid in BPaL regimen (bedaquiline- pretomanid and linezolid for 6-9 mos.) for XDR & MDR-TB. Janssen to hold the rights for bedaquiline (Ex- DS-TB) and linezolid is available from multiple manufacturers- including Mylan
- TB Alliances has also licensed Pretomanid to Mylan for DS & MDR-TB and sublicensed bedaquiline for DS-TB only in BPaMZ regimen (bedaquiline- pretomanid- moxifloxacin and pyrazinamide for 4-6mos.)
- Pretomanid as part of the BPaL regimen is under FDA & EMA review. Mylan gets a non-exclusive & exclusive license to commercialize Pretomanid in low-& middle -income & high-income markets respectively. Janssen will retain exclusive rights to market bedaquiline as part of the combination therapy for MDR-TB
Ref: Mylan | Image: WV News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com